AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27048405 — intervention group
Group type: EXPERIMENTAL
Intervention: PCT-guided therapy
Number of subjects: 550
Study 27048405 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 550
Study 27048405 — intervention group
Group type: EXPERIMENTAL
Intervention: PCT and CRP
Number of subjects: 550
Study 23702257 — intervention group
Group type: EXPERIMENTAL
Intervention: 9.6% carbohydrate‐caffeine‐electrolyte solution with carbohydrate‐electrolyte gels (H‐CHO)
Number of subjects: 14
Study 23702257 — intervention group
Group type: COMPARATOR
Intervention: 5.6% carbohydrate‐electrolyte solution with electrolyte gels (CHO)
Number of subjects: 14
Study 23702257 — intervention group
Group type: COMPARATOR
Intervention: Electrolyte solution and electrolyte gels (PL)
Number of subjects: 14
Study 22184384 — intervention group
Group type: COMPARATOR
Intervention: XP (capecitabine 2,000 mg/m2 per day on days 1 to 14 and cisplatin 60 mg/m2 on day 1, repeated every 3 weeks)
Number of subjects: 458
Study 22184384 — intervention group
Group type: EXPERIMENTAL
Intervention: XP/XRT/XP (two cycles of XP followed by 45-Gy XRT with capecitabine 1,650 mg/m2 per day for 5 weeks and two cycles of XP)
Number of subjects: 458
Study 22184384 — intervention group
Group type: EXPERIMENTAL
Intervention: XP/XRT/XP
Number of subjects: 458
Study 19883407 — intervention group
Group type: EXPERIMENTAL
Intervention: Scheduled maintenance treatment with infliximab (5 mg/kg)
Number of subjects: 0
Study 19883407 — intervention group
Group type: COMPARATOR
Intervention: Standard care (immunomodulators and/or corticosteroids)
Number of subjects: 0
Study 18762502 — intervention group
Group type: EXPERIMENTAL
Intervention: Antichlamydial antimicrobial exposure events (macrolide, tetracycline, quinolone, rifamycin)
Number of subjects: 508
Study 18762502 — intervention group
Group type: EXPERIMENTAL
Intervention: Antichlamydial antimicrobial exposure events
Number of subjects: 508
Study 18762502 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein level
Number of subjects: 508
Study 18762502 — intervention group
Group type: EXPERIMENTAL
Intervention: Recurrent antichlamydial treatments
Number of subjects: 508
Study 15811637 — intervention group
Group type: EXPERIMENTAL
Intervention: Flywheel resistive exercise (FW)
Number of subjects: 25
Study 15811637 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate (Pam)
Number of subjects: 25
Study 15811637 — intervention group
Group type: COMPARATOR
Intervention: Control (Ctrl)
Number of subjects: 25
Study 8749726 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine (150 mg, p.o.)
Number of subjects: 21
Study 8749726 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine (300 mg, p.o.)
Number of subjects: 21
Study 8749726 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine (60 mg, p.o.)
Number of subjects: 21
Study 2049233 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine, sparteine and phenytoin administered as a 'cocktail'
Number of subjects: 8
Study 2049233 — intervention group
Group type: COMPARATOR
Intervention: Single substrate administration of nifedipine, sparteine and phenytoin
Number of subjects: 8
Study 7452209 — intervention group
Group type: EXPERIMENTAL
Intervention: Subliminal message 'mommy and I are one'
Number of subjects: 34
Study 7452209 — intervention group
Group type: COMPARATOR
Intervention: Control group with subliminal message 'people are walking'
Number of subjects: 34
Study 31914094 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified long-axis in-plane ultrasound technique (M-LAINUT)
Number of subjects: 288
Study 31914094 — intervention group
Group type: COMPARATOR
Intervention: Conventional palpation technique (C-PT)
Number of subjects: 288
Study 30801820 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-minute scrub with Betadine (povidone-iodine)
Number of subjects: 101
Study 30801820 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-minute scrub with Betadine (povidone-iodine)
Number of subjects: 101
Study 30801820 — intervention group
Group type: COMPARATOR
Intervention: Comparison of 5-minute vs 10-minute scrub
Number of subjects: 101
Study 28337660 — intervention group
Group type: COMPARATOR
Intervention: Perioperative ECF chemotherapy alone
Number of subjects: 120
Study 28337660 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative ECF chemotherapy with preoperative chemoradiation
Number of subjects: 120
Study 25765043 — intervention group
Group type: EXPERIMENTAL
Intervention: GON blockade with bupivacaine (group B)
Number of subjects: 84
Study 25765043 — intervention group
Group type: COMPARATOR
Intervention: GON blockade with saline (group A)
Number of subjects: 84
Study 25765043 — intervention group
Group type: EXPERIMENTAL
Intervention: GON blockade with bupivacaine (group B) after blinding removed
Number of subjects: 84
Study 25765043 — intervention group
Group type: COMPARATOR
Intervention: GON blockade with saline (group A) after blinding removed
Number of subjects: 84
Study 24014503 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive speed of processing training (SOPT) using InSight software for 20 hours
Number of subjects: 87
Study 24014503 — intervention group
Group type: COMPARATOR
Intervention: No-contact control condition
Number of subjects: 87
Study 20490455 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured patient-clinician communication
Number of subjects: 507
Study 19748858 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise Training (ET)
Number of subjects: 37
Study 17404192 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropinirole 24-hour
Number of subjects: 393
Study 17404192 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 393
Study 15523532 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Electrical Therapy (FET), applied 30 min daily for 3 weeks, during acute hemiplegia (Group A)
Number of subjects: 41
Study 15523532 — intervention group
Group type: COMPARATOR
Intervention: Functional Electrical Therapy (FET), applied 30 min daily for 3 weeks, during chronic hemiplegia (Group B)
Number of subjects: 41
Study 11705338 — intervention group
Group type: EXPERIMENTAL
Intervention: Tape of music with supra- and subliminal messages
Number of subjects: 0
Study 11705338 — intervention group
Group type: EXPERIMENTAL
Intervention: Tape of music with only subliminal messages
Number of subjects: 0
Study 11705338 — intervention group
Group type: EXPERIMENTAL
Intervention: Tape with only music (participants believed it included subliminal messages)
Number of subjects: 0
Study 11705338 — intervention group
Group type: COMPARATOR
Intervention: Waiting group (no tapes)
Number of subjects: 0
Study 9043724 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutrophil-specific filter
Number of subjects: 24
Study 9043724 — intervention group
Group type: COMPARATOR
Intervention: Standard blood filter
Number of subjects: 24
Study 7710234 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous epidural bupivacaine/fentanyl
Number of subjects: 51
Study 7710234 — intervention group
Group type: COMPARATOR
Intervention: Continuous intravenous fentanyl
Number of subjects: 51
Study 2901267 — intervention group
Group type: EXPERIMENTAL
Intervention: Terazosin (1 to 40 mg daily for 3 weeks to 56 months)
Number of subjects: 364
Study 2901267 — intervention group
Group type: EXPERIMENTAL
Intervention: Terazosin in combination with other antihypertensive agents
Number of subjects: 364
Study 2901267 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse effects of Terazosin
Number of subjects: 364
Study 31761974 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 70
Study 31761974 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 30497559 — intervention group
Group type: EXPERIMENTAL
Intervention: FFR-guided CABG
Number of subjects: 100
Study 30497559 — intervention group
Group type: COMPARATOR
Intervention: Angiography-guided CABG
Number of subjects: 100
Study 30497559 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferred lesions (n=24)
Number of subjects: 100
Study 26922379 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacillus coagulans MTCC 5856 tablet containing 2 × 10(9) cfu/day for 90 days
Number of subjects: 36
Study 26922379 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 25693859 — intervention group
Group type: EXPERIMENTAL
Intervention: LCZ696 100 mg (with optional titration to 200 and 400 mg)
Number of subjects: 32
Study 23617229 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimatoprost 0.03% ophthalmic solution applied daily for 9 months
Number of subjects: 20
Study 23617229 — intervention group
Group type: COMPARATOR
Intervention: Vehicle applied nightly for 5 months, followed by re-randomization to either Bimatoprost (Veh-Bim Group) or Vehicle (Veh Group) for 4 months
Number of subjects: 20
Study 20950189 — intervention group
Group type: EXPERIMENTAL
Intervention: Diamond bur
Number of subjects: 60
Study 20950189 — intervention group
Group type: EXPERIMENTAL
Intervention: Air‐abrasion
Number of subjects: 60
Study 20950189 — intervention group
Group type: EXPERIMENTAL
Intervention: Er, Cr: YSGG laser
Number of subjects: 60
Study 20950189 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 60
Study 17601603 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH‐a/chemotherapy
Number of subjects: 115
Study 16615418 — intervention group
Group type: EXPERIMENTAL
Intervention: Stable hypoxemic COPD (HC)
Number of subjects: 28
Study 16615418 — intervention group
Group type: EXPERIMENTAL
Intervention: Stable nonhypoxemic COPD (NHC)
Number of subjects: 28
Study 16615418 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (C)
Number of subjects: 28
Study 12816781 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated soy protein with isoflavones
Number of subjects: 28
Study 12816781 — intervention group
Group type: COMPARATOR
Intervention: Total milk protein
Number of subjects: 28
Study 12816781 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol-washed isolated soy protein with trace isoflavones
Number of subjects: 28
Study 11386482 — intervention group
Group type: EXPERIMENTAL
Intervention: Speech Motor Training (SMT)
Number of subjects: 12
Study 11386482 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended Length of Utterance (ELU)
Number of subjects: 12
Study 8860064 — intervention group
Group type: EXPERIMENTAL
Intervention: Nisoldipine 5 mg twice daily
Number of subjects: 24
Study 8860064 — intervention group
Group type: EXPERIMENTAL
Intervention: Nisoldipine 20 mg once daily
Number of subjects: 24
Study 8860064 — intervention group
Group type: EXPERIMENTAL
Intervention: Nisoldipine 10 mg twice daily
Number of subjects: 24
Study 8860064 — intervention group
Group type: EXPERIMENTAL
Intervention: Nisoldipine 20 mg twice daily
Number of subjects: 24
Study 8860064 — intervention group
Group type: EXPERIMENTAL
Intervention: Nisoldipine therapy
Number of subjects: 24
Study 8860064 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 1298143 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg Bezafibrate retard
Number of subjects: 99
Study 1298143 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 to 80 mg Lovastatin
Number of subjects: 99
Study 1298143 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study 6734453 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil and carmustine (FB)
Number of subjects: 77
Study 6734453 — intervention group
Group type: COMPARATOR
Intervention: 5-fluorouracil, carmustine, and adriamycin (FAB)
Number of subjects: 77
Study 6734453 — intervention group
Group type: EXPERIMENTAL
Intervention: Both FB and FAB
Number of subjects: 77
Study 6734453 — intervention group
Group type: EXPERIMENTAL
Intervention: FAB
Number of subjects: 77
Study 31239111 — intervention group
Group type: EXPERIMENTAL
Intervention: Solifenacin (5 mg per day) for 3 months
Number of subjects: 182
Study 31239111 — intervention group
Group type: COMPARATOR
Intervention: Solifenacin (5 mg per day) for 6 months
Number of subjects: 182
Study 28729200 — intervention group
Group type: EXPERIMENTAL
Intervention: Thicker and creamier test drink (enhanced sensory - ES)
Number of subjects: 119
Study 28729200 — intervention group
Group type: COMPARATOR
Intervention: Thinner test drink (low sensory - LS)
Number of subjects: 119
Study 28729200 — intervention group
Group type: EXPERIMENTAL
Intervention: Test recall condition
Number of subjects: 119
Study 28729200 — intervention group
Group type: COMPARATOR
Intervention: Control recall condition
Number of subjects: 119
Study 25889642 — intervention group
Group type: EXPERIMENTAL
Intervention: Standalone web-based ECG tutorial
Number of subjects: 203
Study 25889642 — intervention group
Group type: COMPARATOR
Intervention: Short follow-up (2-4 weeks)
Number of subjects: 203
Study 25889642 — intervention group
Group type: COMPARATOR
Intervention: Medium follow-up (10-12 weeks)
Number of subjects: 203
Study 25889642 — intervention group
Group type: COMPARATOR
Intervention: Long follow-up (18-20 weeks)
Number of subjects: 203
Study 25889642 — intervention group
Group type: EXPERIMENTAL
Intervention: Junior students
Number of subjects: 203
Study 25889642 — intervention group
Group type: EXPERIMENTAL
Intervention: Senior students
Number of subjects: 203
Study 24001575 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipsilateral hamstring tendon autograft (semitendinosus gracilis)
Number of subjects: 100
Study 24001575 — intervention group
Group type: COMPARATOR
Intervention: Contralateral hamstring tendon autograft (semitendinosus gracilis)
Number of subjects: 100
Study 21366801 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined hepatitis A/B vaccine
Number of subjects: 596
Study 21366801 — intervention group
Group type: COMPARATOR
Intervention: Monovalent hepatitis A and B vaccines
Number of subjects: 596
Study 21366801 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional dose of the same vaccine(s) used for priming
Number of subjects: 596
Study 19479879 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum interferon-alpha activity in untreated juvenile DM patients
Number of subjects: 39
Study 19479879 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum interferon-alpha activity at 36 months postdiagnosis
Number of subjects: 39
Study 17166866 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical abortion
Number of subjects: 78
Study 17166866 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical abortion (mifepristone-misoprostol)
Number of subjects: 78
Study 17166866 — intervention group
Group type: COMPARATOR
Intervention: Both interventions (surgical and medical)
Number of subjects: 78
Study 15094269 — intervention group
Group type: EXPERIMENTAL
Intervention: Nevirapine 400 mg once daily
Number of subjects: 1216
Study 15094269 — intervention group
Group type: EXPERIMENTAL
Intervention: Nevirapine 200 mg twice daily
Number of subjects: 1216
Study 15094269 — intervention group
Group type: EXPERIMENTAL
Intervention: Efavirenz 600 mg once daily
Number of subjects: 1216
Study 15094269 — intervention group
Group type: EXPERIMENTAL
Intervention: Nevirapine (400 mg) and efavirenz (800 mg) once daily
Number of subjects: 1216
Study 15094269 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 1216
Study 15094269 — intervention group
Group type: EXPERIMENTAL
Intervention: Nevirapine plus efavirenz
Number of subjects: 1216
Study 15094269 — intervention group
Group type: EXPERIMENTAL
Intervention: Nevirapine once daily
Number of subjects: 1216
Study 15094269 — intervention group
Group type: COMPARATOR
Intervention: Nevirapine or efavirenz
Number of subjects: 1216
Study 15094269 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of nevirapine and efavirenz
Number of subjects: 1216
Study 11701687 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (10 mg daily)
Number of subjects: 134
Study 11701687 — intervention group
Group type: COMPARATOR
Intervention: Alfacalcidol (1 microg daily)
Number of subjects: 134
Study 9771244 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled salbutamol
Number of subjects: 43
Study 9771244 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone
Number of subjects: 43
Study 9771244 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for both phases)
Number of subjects: 43
Study 7909285 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol 10.5 micrograms
Number of subjects: 160
Study 7909285 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol 21 micrograms
Number of subjects: 160
Study 7909285 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol 42 micrograms
Number of subjects: 160
Study 7909285 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol 84 micrograms
Number of subjects: 160
Study 7909285 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol (all doses)
Number of subjects: 160
Study 7909285 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 3281702 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose dexamethasone (Protocol D)
Number of subjects: 60
Study 3281702 — intervention group
Group type: COMPARATOR
Intervention: Combination of dexamethasone, metoclopramide and diphenhydramine (Protocol DMD)
Number of subjects: 60
Study 3281702 — intervention group
Group type: EXPERIMENTAL
Intervention: Preference for treatment
Number of subjects: 60
Study 31028669 — intervention group
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Number of subjects: 0
Study 31028669 — intervention group
Group type: COMPARATOR
Intervention: Ibrutinib
Number of subjects: 0
Study 31028669 — intervention group
Group type: EXPERIMENTAL
Intervention: Other second-generation BTK inhibitors (acalabrutinib, zanubrutinib, tirabrutinib)
Number of subjects: 0
Study 31028669 — intervention group
Group type: EXPERIMENTAL
Intervention: Reversible BTK inhibitors (vecabrutinib, LOXO-305)
Number of subjects: 0
Study 31028669 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-selective reversible BTK inhibitors (ARQ-531)
Number of subjects: 0
Study 28504364 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term mindfulness meditation (LTM) practice; participants practiced mindfulness meditation just prior to observing others' social pain.
Number of subjects: 0
Study 28504364 — intervention group
Group type: COMPARATOR
Intervention: Control group (matched with LTM practitioners); no specific intervention mentioned.
Number of subjects: 0
Study 26556092 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental Wii Group (n = 16)
Number of subjects: 30
Study 26556092 — intervention group
Group type: COMPARATOR
Intervention: Control Exercise Group (n = 14)
Number of subjects: 30
Study 26556092 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study 23438494 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intake assessment after standard diabetes education
Number of subjects: 699
Study 21531174 — intervention group
Group type: EXPERIMENTAL
Intervention: Gatifloxacin (10 mg/kg once a day for 7 days)
Number of subjects: 844
Study 21531174 — intervention group
Group type: COMPARATOR
Intervention: Chloramphenicol (75 mg/kg per day in four divided doses for 14 days)
Number of subjects: 844
Study 21531174 — intervention group
Group type: EXPERIMENTAL
Intervention: Gatifloxacin
Number of subjects: 844
Study 21531174 — intervention group
Group type: COMPARATOR
Intervention: Chloramphenicol
Number of subjects: 844
Study 18294485 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate (160 mg/d)
Number of subjects: 55
Study 17136556 — intervention group
Group type: EXPERIMENTAL
Intervention: Monoclonal antibodies (e.g., natalizumab)
Number of subjects: 0
Study 17136556 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant beta-interferons and glatiramer acetate (Copaxone)
Number of subjects: 0
Study 17136556 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-beta1b (Betaferon)
Number of subjects: 0
Study 17136556 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Number of subjects: 0
Study 17136556 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasmapheresis
Number of subjects: 0
Study 12937343 — intervention group
Group type: EXPERIMENTAL
Intervention: Fertilase-laser system technology
Number of subjects: 356
Study 11084095 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-site pacing (Group I)
Number of subjects: 26
Study 11084095 — intervention group
Group type: COMPARATOR
Intervention: Single-site (high right atrium) pacing (Group II)
Number of subjects: 26
Study 9342766 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose hypericum extract
Number of subjects: 209
Study 9342766 — intervention group
Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 209
Study 7901064 — intervention group
Group type: EXPERIMENTAL
Intervention: ethinylestradiol/cyproterone acetate (group A)
Number of subjects: 45
Study 7901064 — intervention group
Group type: COMPARATOR
Intervention: D-Tr-6-LHRH (group B)
Number of subjects: 45
Study 3513716 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin (20 micrograms intranasal nightly for three months)
Number of subjects: 46
Study 3513716 — intervention group
Group type: COMPARATOR
Intervention: Enuresis alarm (for three months)
Number of subjects: 46
Study 31858113 — intervention group
Group type: EXPERIMENTAL
Intervention: Preconception marine PUFA concentration
Number of subjects: 346
Study 31858113 — intervention group
Group type: EXPERIMENTAL
Intervention: Preconception SFA concentration
Number of subjects: 346
Study 31858113 — intervention group
Group type: EXPERIMENTAL
Intervention: Preconception trans FA concentration
Number of subjects: 346
Study 31858113 — intervention group
Group type: EXPERIMENTAL
Intervention: FAs at 8 weeks of gestation
Number of subjects: 346
Study 30815063 — intervention group
Group type: EXPERIMENTAL
Intervention: Capturing healthy meals
Number of subjects: 22
Study 30815063 — intervention group
Group type: EXPERIMENTAL
Intervention: Capturing unhealthy meals
Number of subjects: 22
Study 27618460 — intervention group
Group type: EXPERIMENTAL
Intervention: CIL condition (peer-delivered core services of Centers for Independent Living)
Number of subjects: 99
Study 27618460 — intervention group
Group type: COMPARATOR
Intervention: SAU condition (services as usual)
Number of subjects: 99
Study 24911028 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone titrated to 60 mg/d
Number of subjects: 62
Study 24911028 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 24911028 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone (female participants)
Number of subjects: 62
Study 24911028 — intervention group
Group type: COMPARATOR
Intervention: Placebo (female participants)
Number of subjects: 62
Study 24911028 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone (male participants)
Number of subjects: 62
Study 24911028 — intervention group
Group type: COMPARATOR
Intervention: Placebo (male participants)
Number of subjects: 62